The modulatory effects of allopurinol on N-methyl d-aspartate receptors in the central nervous system

Cell Biochemistry and Function

Volumn 30, Issue 8, 2012, Pages 709-710

  Paniz, Lucas ^a   Schmidt, André P ^a,b,c   Souza, Diogo O ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALLOPURINOL; FREE RADICAL; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; XANTHINE OXIDASE;

BRAIN CELL; BRAIN DISEASE; CHRONIC PAIN; DEGRADATION; DOWN REGULATION; EXCITOTOXICITY; HYPERAMMONEMIA; LETTER; NERVE CELL; NEUROMODULATION; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ACETATES; ALLOPURINOL; ANIMALS; HIPPOCAMPUS; MALE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84870692235     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2896     Document Type: Letter

References (21)

1. Yonden Z, Aydin M, Kilbas A, Hilmi D, Sutcu R, Delibas N. Effects of ammonia and allopurinol on rat hippocampal NMDA receptors. Cell Biochem Funct 2010; 28: 159-163. DOI: 10.1002/cbf.1636.
2. Monfort P, Munoz MD, El Ayadi A, Kosenko E, Felipo V. Effects of Hyperammonemia and Liver Failure on Glutamatergic Neurotransmission. Metab Brain Dis 2002; 17: 237-50.
3. Llansola M, Rodrigo R, Monfort P, et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab Brain Dis 2007; 22: 321-335. DOI: 10.1007/s11011-007-9067-0.
4. Schmidt AP, Lara DR, Souza DO. Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Ther 2007; 116: 401-416. DOI: 10.1016/j.pharmthera.2007.07.004.
5. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58: 87-114. DOI: 10.1124/pr.58.1.6.
6. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46: 623-644.
7. Wada Y, Hasegawa H, Nakamura M, Yamaguchi N. Anticonvulsant effect of allopurinol on hippocampal-kindled seizures. Pharmacol Biochem Behav 1992; 42: 899-901.
8. Schmidt AP, Böhmer AE, Antunes C, et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol 2009; 156: 163-172. DOI: 10.1111/j.1476-5381.2008.00025.x.
9. Lara DR, Belmonte-de-Abreu P, Souza DO. Allopurinol for refractory aggression and self-inflicted behaviour. J Psychopharmacol 2000; 14: 81-83. DOI: 10.1177/026988110001400112.
10. Kim P, Yaksh TL, Burnett PC, Blum MR, Sundt TM, Jr. Cerebrospinal fluid levels of uric acid in dogs and the effect of allopurinol. Brain Res 1987; 402: 87-92. DOI: 10.1016/0006-8993(87)91050-X.
11. Marro PJ, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 2006; 1073-74: 444-450. DOI: 10.1016/j.brainres.2005.11.061.
12. Burnstock G, Fredholm BB, Verkhratsky A. Adenosine and ATP receptors in the brain. Curr Top Med Chem 2011; 11(8): 973-1011.
13. Caciagli F, Di Iorio P, Giuliani P, Middlemiss MP, Rathbone MP. The neuroprotective activity of guanosine involves the production of trophic factors and the outflow of purines from astrocytes. Drug Develop Res 2000; 50: 32.
14. Schmidt AP, Paniz L, Schallenberger C, et al. Guanosine Prevents Thermal Hyperalgesia in a Rat Model of Peripheral Mononeuropathy. J Pain 2010; 11: 131-141. DOI: 10.1016/j.jpain.2009.06.010.
15. Schmidt AP, Böhmer AE, Leke R, et al. Antinociceptive effects of intracerebroventricular administration of guanine-based purines in mice: evidences for the mechanism of action. Brain Res 2008; 1234: 50-58. DOI: 10.1016/j.brainres.2008.07.091.
16. Schmidt AP, Lara DR, Maraschin JF, Perla AS, Souza DO. Guanosine and GMP prevent seizures induced by quinolinic acid in mice. Brain Res 2000; 864: 40-43. DOI: 10.1016/S0006-8993(00)02106-5.
17. Lara DR, Schmidt AP, Frizzo MES, Burgos JS, Ramirez G, Souza DO. Effect of orally administered guanosine on seizures and death induced by glutamatergic agents. Brain Res 2001; 912: 176-180. DOI: 10.1016/S0006-8993(01)02734-2.
18. 3H]-guanosine binding sites in rat brain membranes. Br J Pharmacol 2002; 135: 969-976. DOI: 10.1038/sj.bjp.0704542.
19. Frizzo ME, Lara DR, Dahm KC, Prokopiuk AS, Swanson RA, Souza DO. Activation of glutamate uptake by guanosine in primary astrocyte cultures. Neuroreport 2001; 12: 879-81.
20. Tada H, Morooka K, Arimoto K, Matsuo T. Clinical effects of allopurinol on intractable epilepsy. Epilepsia 1991; 32: 279-283.
21. Lara DR, Brunstein MG, Ghisolfi ES, Lobato MI, Belmonte-de-Abreu P, Souza DO. Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol 2001; 16: 235-237.